ReNeuron Group (RENE) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Feb 2016 10:07 AM
RNS
Director Share Purchase
01 Feb 2016 07:00 AM
RNS
Notice of Grant of Key US Patent
12 Jan 2016 07:00 AM
RNS
Pre-clinical data relating to exosome platform
11 Jan 2016 07:00 AM
RNS
Wins UK grant to advance its exosome platform
17 Dec 2015 07:00 AM
RNS
ReNeuron establishes Scientific Advisory Board
07 Dec 2015 07:00 AM
RNS
Interim Results
04 Dec 2015 07:00 AM
RNS
Non-executive Director appointment
12 Nov 2015 02:45 PM
RNS
Notification of Interim Results
06 Nov 2015 03:29 PM
RNS
Total Voting Rights
02 Oct 2015 03:01 PM
RNS
Directors' Interest in Shares and Share Options
28 Sep 2015 12:18 PM
RNS
Block Admission and Total Voting Rights
24 Sep 2015 01:50 PM
RNS
Result of AGM
24 Sep 2015 07:00 AM
RNS
AGM Trading Update
01 Sep 2015 03:22 PM
RNS
Notification of Major Interest in Shares
28 Aug 2015 02:45 PM
RNS
Notification of Major Interest in Shares
28 Aug 2015 07:00 AM
RNS
Notification of Major Interest in Shares
27 Aug 2015 07:01 AM
RNS
Notification of Major Interest in Shares
26 Aug 2015 07:30 AM
RNS
Notification of Major Interest in Shares
26 Aug 2015 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
25 Aug 2015 10:00 AM
RNS
Completion of Placing and TVR
21 Aug 2015 01:45 PM
RNS
Result of General Meeting
29 Jul 2015 04:14 PM
RNS
Publication of Circular and Notice of GM
10 Jul 2015 07:01 AM
RNS
Placing to Raise £68.4 million
10 Jul 2015 07:00 AM
RNS
Preliminary Results
22 Jun 2015 07:00 AM
RNS
Exosome Research Collaboration
11 Jun 2015 07:00 AM
RNS
Senior Management Appointments
29 May 2015 03:00 PM
RNS
NOTIFICATION OF MAJOR INTEREST IN SHARES
22 May 2015 07:00 AM
RNS
FDA Grants Fast Track Designation
15 May 2015 07:00 AM
RNS
Notification of Major Interest in Shares
07 May 2015 07:00 AM
RNS
Notification of Major Interest in Shares
05 May 2015 07:01 AM
RNS
FDA Approves Start of Phase I/II Trial
22 Apr 2015 04:40 PM
RNS
Second Price Monitoring Extn
22 Apr 2015 04:35 PM
RNS
Price Monitoring Extension
17 Apr 2015 12:15 PM
RNS
Long Term Clinical Data from PISCES Stroke Trial
13 Apr 2015 07:00 AM
RNS
IND in the US
01 Apr 2015 07:00 AM
RNS
Reconfigures Board and Strengthens Executive Team
30 Jan 2015 07:00 AM
RNS
Director Share Purchases
13 Jan 2015 03:28 PM
RNS
Notification of Major Interest in Shares
08 Jan 2015 02:46 PM
RNS
Notification of Major Interest in Shares
17 Nov 2014 07:00 AM
RNS
Interim Results
30 Oct 2014 07:00 AM
RNS
Notification of Interim Results
14 Oct 2014 07:00 AM
RNS
Notification of Major Interest in Shares
22 Sep 2014 07:00 AM
RNS
Directors' Interest in Shares and Share Options
15 Sep 2014 12:15 PM
RNS
Block Listing Six Monthly Review
08 Sep 2014 07:00 AM
RNS
Appointment of CEO
03 Sep 2014 07:00 AM
RNS
Notification of Major Interest in Shares
02 Sep 2014 11:30 AM
RNS
Result of 2014 Annual General Meeting
02 Sep 2014 07:00 AM
RNS
AGM Trading Update
19 Aug 2014 09:00 AM
RNS
Notification of Major Interest in Shares
25 Jul 2014 09:59 AM
RNS
Director/PDMR Shareholding

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

It listed on AIM in 2006 under the ticker RENE.

UK 100

Latest directors dealings